Literature DB >> 18755924

The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study.

Richard B Hubbard1, Chris Smith, Ivan Le Jeune, Jonathan Gribbin, Andrew W Fogarty.   

Abstract

RATIONALE: Previous studies have suggested that people with idiopathic pulmonary fibrosis (IPF) may be at increased risk of vascular disease.
OBJECTIVES: To quantify the risk of cardiovascular disease before and after a diagnosis of IPF.
METHODS: We used computerized primary care data from the Health Improvement Network to quantify the relative risk of having a cardiovascular event (acute coronary syndrome, angina, atrial fibrillation, deep-vein thrombosis, and cerebrovascular accident) either before or after having a diagnosis of IPF in comparison to age, sex, and community-matched general population control subjects.
MEASUREMENTS AND MAIN RESULTS: Our study included 920 incident case subjects of IPF (mean age at diagnosis, 71 yr; 62% male) and 3,593 matched control subjects. There was an increased risk of acute coronary syndrome (odds ratio [OR], 1.53; 95% confidence interval [CI], 1.15-2.03), angina (OR, 1.84; 95% CI, 1.48-2.29) and deep-vein thrombosis (OR, 1.98; 95% CI, 1.13-3.48) in the period before the diagnosis of IPF. During the follow-up period, there was a marked increased risk of acute coronary syndrome (rate ratio [RR], 3.14; 95%CI, 2.02-4.87) and deep-vein thrombosis (RR, 3.39; 95% CI, 1.57-7.28). None of these estimates were confounded by smoking habit or modified by age or sex.
CONCLUSIONS: People with IPF have an increased risk of vascular disease in comparison with the general population. This effect is most marked for acute coronary syndrome and deep-vein thrombosis after the diagnosis of IPF has been made.

Entities:  

Mesh:

Year:  2008        PMID: 18755924     DOI: 10.1164/rccm.200805-725OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  66 in total

1.  Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

Review 3.  Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Boonphiphop Boonpheng; Patompong Ungprasert
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

5.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

Authors:  D B Sprunger; A L Olson; T J Huie; E R Fernandez-Perez; A Fischer; J J Solomon; K K Brown; J J Swigris
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

6.  Association between C-reactive protein and carotid plaque in mild-to-moderate idiopathic pulmonary fibrosis.

Authors:  Andrea Sonaglioni; Antonella Caminati; Roberto Lipsi; Michele Lombardo; Sergio Harari
Journal:  Intern Emerg Med       Date:  2021-01-07       Impact factor: 3.397

7.  Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.

Authors:  Jin-Fu Xu; George R Washko; Kiichi Nakahira; Hiroto Hatabu; Avignat S Patel; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; Alejandro A Diaz; Hui-Ping Li; Jie-Ming Qu; Blanca E Himes; Carolyn E Come; Katherine D'Aco; Fernando J Martinez; MeiLan K Han; David A Lynch; James D Crapo; Danielle Morse; Stefan W Ryter; Edwin K Silverman; Ivan O Rosas; Augustine M K Choi; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-12       Impact factor: 21.405

Review 8.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 9.  Cardiac manifestations of idiopathic pulmonary fibrosis.

Authors:  Abhinav Agrawal; Isha Verma; Varun Shah; Abhishek Agarwal; Rutuja R Sikachi
Journal:  Intractable Rare Dis Res       Date:  2016-05

10.  MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study.

Authors:  Effrosyni D Manali; Panagiotis Lyberopoulos; Christina Triantafillidou; Likourgos F Kolilekas; Christina Sotiropoulou; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  BMC Pulm Med       Date:  2010-05-28       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.